p53 Isoforms as Cancer Biomarkers and Therapeutic Targets

16Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

Abstract

This review aims to summarize the implications of the major isoforms of the tumor suppressor protein p53 in aggressive cancer development. The current knowledge of p53 isoforms, their involvement in cell-signaling pathways, and their interactions with other cellular proteins or factors suggests the existence of an intricate molecular network that regulates their oncogenic function. Moreover, existing literature about the involvement of the p53 isoforms in various cancers leads to the proposition of therapeutic solutions by altering the cellular levels of the p53 isoforms. This review thus summarizes how the major p53 isoforms Δ40p53α/β/γ, Δ133p53α/β/γ, and Δ160p53α/β/γ might have clinical relevance in the diagnosis and effective treatments of cancer.

Cite

CITATION STYLE

APA

Zhao, L., & Sanyal, S. (2022, July 1). p53 Isoforms as Cancer Biomarkers and Therapeutic Targets. Cancers. MDPI. https://doi.org/10.3390/cancers14133145

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free